



## Deprol advertisement.


[s.l.]: [s.n.], 1958

<https://digital.library.wisc.edu/1711.dl/NH7P7YEOWZCSM8S>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.



relieves  
depression  
during  
pregnancy  
and  
postpartum

*acts promptly*—controls the syndrome of mental depression *without* C.N.S. excitation; reduces depressive rumination and crying; restores natural sleep without barbiturate-like hangover.

*significantly different*—unlike amine-oxidase inhibiting energizers, Deprol produces no liver toxicity and does not adversely affect blood pressure; unlike C.N.S. stimulants, Deprol has no depressive aftereffects, does not cause insomnia or depress appetite.

# Deprol<sup>†</sup>

**Dosage:** Usual starting dose is 1 tablet q.i.d. When necessary, this dose may be gradually increased up to 3 tablets q.i.d.

**Composition:** Each tablet contains 400 mg. mepro-

bamate and 1 mg. 2-diethylaminoethyl benzilate hydrochloride (benactyzine HCl).

**Supplied:** Bottles of 50 scored tablets.

1. Current personal communications; in the files of Wallace Laboratories. 2. Alexander, L.: Chemotherapy of depression—Use of meprobamate combined with benactyzine (2-diethylaminoethyl benzilate) hydrochloride. J.A.M.A. **166**:1019, March 1, 1958.



WALLACE LABORATORIES, New Brunswick, N. J. Literature and samples on request

CO-7754

TRADE-MARK